Canaccord Genuity Maintains Buy on Sigilon Therapeutics, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Sigilon Therapeutics (NASDAQ:SGTX) and raises the price target from $6 to $30.

July 05, 2023 | 11:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Sigilon Therapeutics and raises the price target from $6 to $30.
The news of Canaccord Genuity maintaining a Buy rating and raising the price target for Sigilon Therapeutics from $6 to $30 is likely to have a positive impact on the company's stock in the short term. This is because such an upgrade usually signals the analyst's increased confidence in the company's future performance, which can attract more investors and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100